FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976211833> ?p ?o ?g. }

• W1976211833 endingPage "S151" @default.
• W1976211833 startingPage "S151" @default.
• W1976211833 abstract "We prospectively evaluated survival after NST dUCBT for poor risk acute leukemia or lymphoma (excluding mantle cell) in patients without a suitably matched related donor. Eligible were patients aged ≤ 70 years with adequate organ function (ejection fraction > 35%; lung function > 50% predicted; total bilirubin ≤ 2.5 mg/dl, liver enzymes < 5 × upper limit of normal; CrCl > 40 mL/min/1.73m2), performance score (PS) ≥ 60, and > 3 months after prior autologous transplant. The preparative regimen consisted of fludarabine 40 mg/m2 IV days –6 to -2, cyclophosphamide 50 mg/kg IV day -6, total body irradiation 200 cGy day –1 and immunosuppression with a calcineurin inhibitor and mycophenolate mofetil. G-CSF started at day +1. All patients received dUCB grafts HLA-matched 4-6/6 (A and B at antigen level, DRB1 allele level) to the patient and to each other. Fifty-four patients were enrolled from 16 centers; 4 of 54 patients were excluded due to progressive disease prior to dUCBT (n = 3) and 1 withdrew consent. The median age was 58 yrs (range, 16-69) and weight, 79kg (range, 46-119). Thirty-six patients had acute leukemia (64% were in CR1) and 14 patients had lymphoma. Six patients (12%) had a prior autologous transplant. The median infused combined nucleated cell dose was 4.2 × 107/kg (2.3-13.6). Fifty-three percent of the units were 4/6 and 39% were 5/6 HLA-matched to the recipient; 66% of patients received at least one 4/6 HLA-matched unit. Most patients (80%) had PS 90-100. The median follow-up of survivors was 364 days (range, 154-381). The 6-month probability of overall survival was 72% (95%CI, 56-83%) and progression-free survival 63% (95%CI, 48-76%). The cumulative incidence of treatment-related mortality at day-180 was 20% (95%CI, 8-31%) and relapse/progression, 14% (95%CI, 4-24%). Eighteen patients died and relapse/progression was the most common cause (N = 9). The cumulative incidence of grade II-IV acute GVHD at day 56 is 36% (95%CI, 22-50%) and grade III-IV 10% (95%CI, 2-19%) and chronic GVHD at 180 days was 13% (5%CI, 3-24%). The cumulative incidence of neutrophil recovery at day 56 was 94.0% (95%CI, 87-100.0%) at a median time of 17 days (range, 6-45). Three patients had primary and 1 secondary graft failure. These data demonstrate that NST dUCBT is safe, reproduced results from single centers in the multicenter setting, and establishes the framework for randomized trials to study alternative donor NST transplantation for hematologic malignancies." @default.
• W1976211833 created "2016-06-24" @default.
• W1976211833 creator A5007847102 @default.
• W1976211833 creator A5012632915 @default.
• W1976211833 creator A5025342328 @default.
• W1976211833 creator A5029278364 @default.
• W1976211833 creator A5033267787 @default.
• W1976211833 creator A5040328429 @default.
• W1976211833 creator A5041346359 @default.
• W1976211833 creator A5044257217 @default.
• W1976211833 creator A5045583767 @default.
• W1976211833 creator A5052927157 @default.
• W1976211833 creator A5065373363 @default.
• W1976211833 date "2011-02-01" @default.
• W1976211833 modified "2023-09-30" @default.
• W1976211833 title "Phase II Trial of Non-Myeloablative Conditioning (NST) Double Umbilical Cord Blood Transplantation (DUCBT) From Unrelated Donors in Patients With Hematologic Malignancies: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0604" @default.
• W1976211833 doi "https://doi.org/10.1016/j.bbmt.2010.12.006" @default.
• W1976211833 hasPublicationYear "2011" @default.
• W1976211833 type Work @default.
• W1976211833 sameAs 1976211833 @default.
• W1976211833 citedByCount "1" @default.
• W1976211833 countsByYear W19762118332012 @default.
• W1976211833 crossrefType "journal-article" @default.
• W1976211833 hasAuthorship W1976211833A5007847102 @default.
• W1976211833 hasAuthorship W1976211833A5012632915 @default.
• W1976211833 hasAuthorship W1976211833A5025342328 @default.
• W1976211833 hasAuthorship W1976211833A5029278364 @default.
• W1976211833 hasAuthorship W1976211833A5033267787 @default.
• W1976211833 hasAuthorship W1976211833A5040328429 @default.
• W1976211833 hasAuthorship W1976211833A5041346359 @default.
• W1976211833 hasAuthorship W1976211833A5044257217 @default.
• W1976211833 hasAuthorship W1976211833A5045583767 @default.
• W1976211833 hasAuthorship W1976211833A5052927157 @default.
• W1976211833 hasAuthorship W1976211833A5065373363 @default.
• W1976211833 hasConcept C126322002 @default.
• W1976211833 hasConcept C141071460 @default.
• W1976211833 hasConcept C2776694085 @default.
• W1976211833 hasConcept C2776755627 @default.
• W1976211833 hasConcept C2778880498 @default.
• W1976211833 hasConcept C2779263901 @default.
• W1976211833 hasConcept C2780252810 @default.
• W1976211833 hasConcept C2911091166 @default.
• W1976211833 hasConcept C71924100 @default.
• W1976211833 hasConcept C90924648 @default.
• W1976211833 hasConceptScore W1976211833C126322002 @default.
• W1976211833 hasConceptScore W1976211833C141071460 @default.
• W1976211833 hasConceptScore W1976211833C2776694085 @default.
• W1976211833 hasConceptScore W1976211833C2776755627 @default.
• W1976211833 hasConceptScore W1976211833C2778880498 @default.
• W1976211833 hasConceptScore W1976211833C2779263901 @default.
• W1976211833 hasConceptScore W1976211833C2780252810 @default.
• W1976211833 hasConceptScore W1976211833C2911091166 @default.
• W1976211833 hasConceptScore W1976211833C71924100 @default.
• W1976211833 hasConceptScore W1976211833C90924648 @default.
• W1976211833 hasIssue "2" @default.
• W1976211833 hasLocation W19762118331 @default.
• W1976211833 hasOpenAccess W1976211833 @default.
• W1976211833 hasPrimaryLocation W19762118331 @default.
• W1976211833 hasRelatedWork W1966485586 @default.
• W1976211833 hasRelatedWork W1967892979 @default.
• W1976211833 hasRelatedWork W2020725971 @default.
• W1976211833 hasRelatedWork W2783354986 @default.
• W1976211833 hasRelatedWork W2981183011 @default.
• W1976211833 hasRelatedWork W3039238309 @default.
• W1976211833 hasRelatedWork W4296614183 @default.
• W1976211833 hasRelatedWork W4318777463 @default.
• W1976211833 hasRelatedWork W4319262932 @default.
• W1976211833 hasRelatedWork W4319263100 @default.
• W1976211833 hasVolume "17" @default.
• W1976211833 isParatext "false" @default.
• W1976211833 isRetracted "false" @default.
• W1976211833 magId "1976211833" @default.
• W1976211833 workType "article" @default.